Allogeneic sibling umbilical-cord-blood transplantation in children with malignant and non-malignant disease

John E Wagner, Michael Steinbuch, Nancy A. Kernan, Hal E. Broxmayer, Eliane Gluckman

Research output: Contribution to journalArticlepeer-review

546 Scopus citations

Abstract

Allogeneic bone marrow transplantation is limited by the availability of suitable marrow donors and risk of graft-versus-host disease (GVHD) and opportunistic infection. In an attempt to ameliorate these limitations, umbilical cord blood has been postulated as an alternative source of allogeneic haemopoietic stem cells for transplantation. From September, 1994, umbilical cord blood from sibling donors has been used to reconstitute haemapoiesis in 44 children with acquired or congenital lympho-haemapoietic disorders, neuroblastoma, or metabolic diseases. Patients who had HLA-identical and HLA-1 antigen disparate grafts, had a probability of engraftment at 50 days after transplantation of 85%. No patient had late graft failure. The probability of grade II-IV GVHD at 100 days was 3% and the probability of chronic GVHD at one year was 6%. With a median follow-up of 1·6 years, the probability of survival for recipients of HLA-identical or HLA-1 antigen disparate grafts is 72%. We conclude that umbilical cord blood is a sufficient source of transplantable haemopoietic stem cells for children with HLA-identical or HLA-1 antigen disparate sibling donors with very low risk of acute or extensive chronic GVHD. The feasibility of umbilical-cord-blood transplantation with HLA-2 and HLA-3 antigen disparate sibling donors remains to be determined.

Original languageEnglish (US)
Pages (from-to)214-219
Number of pages6
JournalThe Lancet
Volume346
Issue number8969
DOIs
StatePublished - Jul 22 1995

Bibliographical note

Funding Information:
R Pahwa, Schneider Children’s Hospital, New Hyde Park, New York, USA (n=l); N Bunin, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA (n= 1); S Neudorf, Children’s Hospital of Pittsburgh, Pittsburgh, Pennsylvania, USA (n= 1); A Nagler, Hadassah University, Jerusalem, Israel (n=l); and F Falkenberg, University Medical Center, Leiden, The Netherlands (n= 1). The authors gratefully acknowledge Todd DeFor, for his diligence and careful analysis of the data, and Judith Bard for her critical review of the manuscript. The study was supported by grants from the Childrens Cancer Research Fund (JEW, MS), National Institutes of Health Grant No POI-CA21737 (MS) and American Cancer Society Career Development Award No 91-56 (JEW) ; National Institutes of Health Grant Cytokine No PO1-AI32918 (NAK) and Leukemia No P01-CA23766 (NAK) and Zelda Weintraub Cancer Foundation (NAK); National Institutes of Health Grant No ROI-HL46549 (HEB).

Fingerprint

Dive into the research topics of 'Allogeneic sibling umbilical-cord-blood transplantation in children with malignant and non-malignant disease'. Together they form a unique fingerprint.

Cite this